Design and Synthesis of a Tetrahydroisoquinoline-Based Hydroxamate Derivative (ZYJ-34v), An Oral Active Histone Deacetylase Inhibitor with Potent Antitumor Activity

Authors


Corresponding author: Wenfang Xu, wfxu@yahoo.cn

Abstract

In our previous study, we developed a novel series of tetrahydroisoquinoline-based hydroxamic acid derivatives as histone deacetylase inhibitors (Bioorg Med Chem, 2010, 18, 1761–1772; J Med Chem, 2011, 54, 2823–2838), among which, compound ZYJ-34c (1) was identified and validated as the most potent one with marked in vitro and in vivo antitumor potency (J Med Chem, 2011, 54, 5532–5539.). Herein, further modification in 1 afforded another oral active analog ZYJ-34v (2) with simplified structure and lower molecular weight. Biological evaluation of compound 2 showed efficacious inhibition against histone deacetylase 1, 2, 3, and 6, which was confirmed by Western blot analysis results. Most importantly, compound 2 exhibited similar even more potent in vitro and in vivo antitumor activities relative to the approved histone deacetylase inhibitor SAHA.

Ancillary